Shaanxi Kanghui Pharmaceutical announced that Shandong Youbang, a subsidiary of the company's controlling shareholder, Lai Xinsheng, should compensate the company with RMB 269.0942 million. Lai Xinsheng intends to transfer its 49% equity in Shandong Youbang to Hongfu Pharmaceutical for a transfer price of RMB 14.27 million, of which RMB 8.3 million will be directly paid to the company by Hongfu Pharmaceutical to repay Lai Xinsheng's performance compensation. The compensation is still short of RMB 260.7942 million, and the company requires Lai Xinsheng to continue to perform the compensation obligation. If Lai Xinsheng fails to perform the compensation obligation, the company will pursue legal action against Lai Xinsheng. The company waived its preemptive right to purchase the 49% equity in Shandong Youbang. After waiving the preemptive right, the company still holds 51% equity in Shandong Youbang, and the scope of the company's consolidated financial statements has not changed.
康惠制药：放弃控股子公司山东友帮49%股权的优先购买权
Shaanxi Kanghui Pharmaceutical: Waives the priority purchase right for 49% equity of Shandong Youbang subsidiary.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.